Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate
outcomes selection in early clinical trials is key to maximizing the likelihood of identifying …

Highlights•Clinical Pharmacology is an essential part of the Neurosciences Drug Discovery
process.•In recent years there has been an emphasis on First Time in Human safety and …

A recent article identified five key technical determinants that make substantial contributions
to the outcome of drug R&D projects (Lessons learned from the fate of AstraZeneca's drug …

Translating laboratory discoveries into successful therapeutics can be difficult. Clinical Trials
in Neurology aims to improve the efficiency of clinical trials and the development of …

The paucity of novel drugs for neuropsychiatric indications contrasts with the remarkable
recent advances in neuroscience research. We have identified 5 challenges the field needs …

Although clinical trials were virtually unheard of in psychiatry for many years, they are now
the gold standard for judging whether drugs are safe and useful. But should they be? What …

There is growing awareness among many in the pharmaceutical industry and research
community that psychopharmacologic drug development is approaching a crisis because of …

The standard randomized controlled trial design is still based on the acute disease model.
This is in sharp contrast with the fact that the patient is likely to have experienced other …

The clinical guidelines that underpin the use of drugs for mental disorders are informed by
evidence from randomised controlled trials (RCTs). RCTs are performed to obtain marketing …

Despite considerable progress in pharmacotherapy over the past seven decades, many
mental disorders remain insufficiently treated. This situation is in part due to the limited …